BRCA mutations are the main known hereditary factors for ovarian cancer. Notably, emerging evidence has led to considerable interest in the role of sirtuin 1 (SIRT1) in ovarian cancer development. However, dynamic crosstalk between BRCA1 and SIRT1 is poorly understood. Here, we showed that: (i) BRCA1 inactivation events (mutation, promoter methylation, or knockdown) were accompanied by decreased SIRT1 levels and increased nicotinamide adenine dinucleotide (NAD) levels and a subsequent increase in SIRT1 activity; (ii) overexpression of BRCA1 resulted in increased SIRT1 levels, an impairment in NAD synthesis, and a subsequent inhibition of SIRT1 activity; and (iii) intracellular NAD levels were largely responsible for regulating SIRT1 activity, and BRCA1 expression patterns correlated with SIRT1 levels and NAD levels correlated with SIRT1 activity in human ovarian cancer specimens. Interestingly, although BRCA1 inactivation events inhibited SIRT1 expression, they led to a substantial increase in NAD levels that enhanced NAD-related SIRT1 activity. This is a special BRCA1-mediated compensatory mechanism for the maintenance of SIRT1 function. Therefore, these results highlight a novel interaction between BRCA1 and SIRT1, which may be beneficial for the dynamic balance between BRCA1-related biologic processes and SIRT1-related energy metabolism and stress response.
adjacent normal tissue, BRCA1-mutated ovarian cancer showed dramatically decreased intracellular levels of SIRT1 compared with adjacent normal tissue ( Fig. 1b ). Intracellular SIRT1 activity was increased in BRCA1-mutated ovarian cancer compared with adjacent normal tissue, but there was no significant difference in SIRT1 activity between non-BRCA1-mutated ovarian cancer and the adjacent normal tissue (Fig. 1c ). In addition, although intracellular NAD levels and SIRT1 levels were also increased in non-BRCA2-mutated and BRCA2-mutated ovarian cancers compared with their adjacent normal tissue, there was no significant difference between the non-BRCA2-mutated and BRCA2-mutated groups, including ovarian cancer and normal ovarian tissues ( Figs. 1d and e ). It should be noted that there was no significant difference in SIRT1 activity among the four groups (Fig. 1f ). Therefore, these results suggest that BRCA1 inactivation may be involved in the inhibition of SIRT1 expression and elevated SIRT1 activity. BRCA1 inactivity mediated by promoter hypermethylation is accompanied by suppression of SIRT1 expression and increased SIRT1 activity. In mammals, promoter methylation is an epigenetic modification involved in regulating gene expression 6, 8, 9 . Consistent with this idea, we showed that ovarian cancer tissue with a hypermethylated BRCA1 promoter ( Fig. 2a and b ) displayed reduced expression of BRCA1 ( Fig. 2c ) compared with adjacent normal tissue. Based on these considerations, the low levels of BRCA1 mediated by promoter hypermethylation were an appropriate model for investigating the physiologic relationship between BRCA1 status and SIRT1 expression or activity. Notably, there was a marked increase in NAD levels (Fig. 2d ) accompanied by enhanced SIRT1 activity ( Fig. 2f ) and a significant decrease in SIRT1 levels ( Fig. 2e ), along with a hypermethylated promoter-mediated BRCA1 deficiency. In addition, we analyzed the correlation between BRCA1 levels or NAD levels and SIRT1 levels or SIRT1 activity in 34 ovarian cancer samples (Figs. 2g-j). It is interesting to note that a significant positive correlation was only observed between levels of BRCA1 and SIRT1 (R 5 0.545, P , 0.001; Fig. 2g ) and between NAD levels and SIRT1 activity (R 5 0.666, P , 0.001; Fig. 2j ). These results indicate that BRCA1 may be responsible for the regulation of SIRT1 expression and NAD-related SIRT1 activity.
BRCA1 can regulate intracellular SIRT1 levels and NAD-related SIRT1 activity in ovarian cancer cells. To confirm the role of BRCA1 in the regulation of SIRT1 expression and activity, the effects of knockdown or overexpression of BRCA1 were evaluated in three ovarian cancer cell lines (A2780, SKOV-3, and CAOV-3) and primary ovarian cancer cells with identified BRCA1 mutations or no BRCA1 mutations. The results indicated that: (i) overexpression of BRCA1 could effectively reduce the NAD levels in A2780 and primary non-BRCA1-mutated and BRCA1-mutated ovarian cancer cells; (ii) knockdown of BRCA1 was an effective way to induce an increase of NAD levels in A2780 and primary non-BRCA1-mutated ovarian cancer cells, but NAD levels were not sensitive to BRCA1 knockdown in primary BRCA1-mutated ovarian cancer cells; and (iii) there were no significant changes in NAD levels after the knockdown or overexpression of BRCA1 in SKOV-3 and CAOV-3 cells ( Fig. 3a) . Interestingly, the changes in intracellular NAD levels were consistent with the tendency of SIRT1 activity ( Fig. 3d ) rather than the intracellular SIRT1 levels ( Fig. 3b and c). In addition, knockdown or overexpression of BRCA1 was an effective way to inhibit or induce SIRT1 expression, respectively ( Fig. 3b and c), but SIRT1 levels were not sensitive to BRCA1 knockdown in primary BRCA1-mutated ovarian cancer cells.
Intracellular NAD can induce SIRT1 activity but not SIRT1 expression in ovarian cancer cells. To further confirm the role of intracellular NAD levels in the regulation of SIRT1 activity, the effects of incubation with different concentrations of NAD and knockdown or overexpression of nicotinamide phosphoribosyltransferase (Nampt) were evaluated in ovarian cancer cell line A2780 and primary ovarian cancer cells with identified BRCA1 mutations or no BRCA1 mutations, due to these cells were sensitive to changes in NAD levels mediated by BRCA1 (as shown in Fig. 3a ). SIRT1 activity was increased ( Fig. 4b) , accompanied by increased levels of intracellular NAD (Fig. 4a ). However, intracellular SIRT1 levels were not sensitive to incubation with extracellular NAD in ovarian cancer cells ( Fig. 4c and d) . It is well known that Nampt is a rate-limiting enzyme in regenerating NAD in mammals. The results indicate that knockdown or overexpression of Nampt could effectively reduce or increase NAD levels in ovarian cancer cells ( Fig. 4e ). Also, reduced or increased NAD levels mediated by Nampt could effectively inhibit or induce SIRT1 activity ( Fig. 4f ), but not influence SIRT1 levels in ovarian cancer cells ( Fig. 4g and h). These results suggest that BRCA1-mediated NAD synthesis may be responsible for the induction of SIRT1 activity.
Intracellular NAD can feedback activate BRCA1 expression in ovarian cancer cells. As already known, SIRT1 overactivation results in NAD depletion, and our previous study suggested that NAD may be a positive regulator for BRCA1 transcription in ovarian cancer cells 17 . Therefore, it can be speculated that SIRT1 overactivation-mediated NAD consumption may inhibit BRCA1 function. To confirm the role of SIRT1-related NAD levels in the regulation of BRCA1 levels, the effects of knockdown or overexpression of SIRT1 and incubation with different concentrations of NAD were evaluated in ovarian cancer cell line A2780 and primary ovarian cancer cells with identified BRCA1 mutations or no BRCA1 mutations, due to these cells were sensitive to changes in NAD levels mediated by BRCA1 (as shown in Fig. 3a) . Notably, we observed that BRCA1 expression was upregulated, along with increased levels of intracellular NAD (Fig. 5a ). In addition, increased or reduced NAD levels ( Fig. 5b ) mediated by the knockdown or overexpression of SIRT1 could effectively induce or inhibit BRCA1 expression in A2780 and primary non-BRCA1mutated ovarian cancer cells ( Fig. 5c ). Relative BRCA1 levels Normal Cancer N o r m a l C a n c e r N o r m a l C a n c e r N o r m a l C a n c e r P = 0.0235 P = 0.0043 
-258 -379 -647 bp -189 Position: Fig. 2a . The y-axis shows the mean number of methylation sites. (c-f), BRCA1 levels, NAD levels, and SIRT1 levels and activity were measured in ovarian cancer with an identified hypermethylated BRCA1 promoter and compared with those of adjacent normal tissue (unmethylated BRCA1 promoter). Bar graphs show mean 6 SD (each group, n 5 13). (g and h), Correlation between BRCA1 levels and SIRT1 levels or SIRT1 activity in ovarian cancer tissues (each group, n 5 34). (i and j), Correlation between NAD levels and SIRT1 levels or SIRT1 activity in ovarian cancer tissues (Each group, n 5 34).
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Discussion
In this study, we report for the first time that BRCA1 is a positive regulator of SIRT1 levels and a negative regulator of NAD-related SIRT1 activity. Interestingly, the work presented here provides direct evidence that a BRCA1-mediated switch between SIRT1 expression and activity may have significant physiological roles in the maintenance of SIRT1-related biological processes in vivo (Fig. 6 ). However, NAD levels and SIRT1 expression and activity were not affected by BRCA1 knockdown in primary BRCA1-mutated ovarian cancer cells. It can be speculated that a lack of function of BRCA1 knockdown-mediated NAD or SIRT1 regulation, which may be due to BRCA1 itself, has no function along with BRCA1-mutation. In addition, as shown in Fig. 4 , intracellular NAD levels may be responsible for the induction of SIRT1 activity, but we observed that non-BRCA1-mutated ovarian cancer tissues harbored higher levels of NAD ( Fig. 1a ), but not higher levels of SIRT1 activity (Fig. 1c) . The reason for this disparity is currently unknown but appear to comprise more complex regulatory mechanisms in ovarian cancer.
Notably, these observations further correlate the physiological properties of BRCA1 with SIRT1-related metabolism in ovarian cancer cells. For example, (i) BRCA1 inactivation not only increases reactive oxygen species generation, but also activates protective autophagy 13, 18 . SIRT1 can positively regulate autophagy under oxidative stress 19 . In this regard, SIRT1 expression and imbalance in its activity may be involved in BRCA1-related oxidative stress and autophagy; (ii) Endoplasmic reticulum (ER) stress signaling plays an important part in the induction of BRCA1 expression 20 . However, ER stress can be attenuated by a SIRT1-dependent mechanism 21, 22 . Therefore, BRCA1-related elevated levels of SIRT1 may resist the adverse effects of ER stress; (iii) Both NAD and SIRT1 play pivotal roles in cell proliferation 23, 24 , a substantial body of evidence indicates that loss of function of the tumor suppressor gene BRCA1 plays an important role in promoting cancer cell proliferation and survival 25, 26 . One can speculate that effects of BRCA1 on cell proliferation, which may involve in SIRT1 due to BRCA1 as a metabolic switch for NAD and SIRT1 17 . However, to date, it is not fully understood how the direct or indirect interaction between BRCA1 and SIRT1 at the molecular level. But some insight was gained by a previous study that BRCA1 serves as a positive regulator of SIRT1 by binding to the promoter region 27, 28 . These results together with our previous finding provided two novel pathways of BRCA1-NAD-SIRT1 activity and SIRT1-NAD-BRCA1 function (Fig. 6) 17 . The crosstalk may be beneficial for the dynamic balance between BRCA1-related biologic processes such as cell cycle progression, apoptosis, DNA damage repair, transcription regulation, and SIRT1-related energy metabolism and stress responses. All of this may improve our understanding of the basic molecular mechanism underlying BRCA1-and SIRT1-related ovarian cancer progression. Patients and tissue collection. Serous ovarian cancer patients were enrolled between 2010 and 2012, and all patients gave informed consent. Fresh tumor samples, adjacent normal ovarian tissues, ascites, and blood samples were obtained at the time of primary surgery before any chemotherapy or radiotherapy (20 pairs of BRCA1mutated or not, 16 pairs of BRCA2-mutated or not, and 13 pairs with hypermethylated BRCA1 promoter or not). Hematoxylin and eosin staining of the samples for histopathologic diagnosis and grading were performed by three staff pathologists using World Health Organization criteria. All patients were screened for BRCA1 and BRCA2 mutations by multiplex polymerase chain reaction (PCR). Their characteristics are given in Supplementary Table S1 and Table S2 .
Cell culture and lentiviral transfection. Primary ovarian cancer cells were obtained from the ascites of patients undergoing surgery for ovarian cancer and cultured in RPMI 1640 with 10% fetal bovine serum (Invitrogen, CA, USA) as previously reported [4] [5] [6] . Human A2780, SKOV-3, and CAOV-3 ovarian cancer cells were maintained in Dulbecco's Modified Eagles Medium (DMEM) with 10% fetal bovine serum (Invitrogen). Lentiviral vectors expressing short hairpin RNAs (shRNAs) against BRCA1 (NM_007299) were obtained from GeneChem Co., Ltd (Shanghai, China), the synthesized sequences are shown in Supplementary Table S3 . The nonsilencing shRNA sequence was used as a negative control; the synthesized sequences are shown in Supplementary Table S3 . The shRNA lentiviral particles for Nampt (sc-45843-V) and SIRT1 (sc-40986-V) were purchased from Santa Cruz Biotechnology (CA, USA). For overexpression of BRCA1, Nampt or SIRT1, the open reading frames of BRCA1 (NM_007299), Nampt (NM_005746) or SIRT1 (NM_012238) were respectively cloned into the lentiviral vector GV287 (Ubi-MCS-3FLAG-SV40-EGFP; GeneChem Co., Ltd). Transfections were performed using polybrene and enhanced infection solution (GeneChem Co., Ltd) according to the manufacturer's recommended protocol. The efficiency of BRCA1, Nampt or SIRT1 knockdown and overexpression and the procedures were as previously reported 17 .
Real-time quantitative PCR. Total RNA was extracted using Trizol reagents (Invitrogen) according to the manufacturer's protocol. DNA contamination was removed by adding DNase I (Invitrogen) according to the manufacturer's protocol. Total RNA was then reverse-transcribed from 2 mg of RNA using the PrimeScript RT Master Mix kit (TaKaRa, Dalian, China) and amplified by SYBR Premix Ex TaqTM II (TaKaRa) in a Roche LightCycler 2.0 instrument (Roche Diagnostics, Mannheim, Germany). The specific primer sequences for BRCA1, SIRT1 and Nampt were shown in Supplementary Table S3 . GAPDH mRNA was amplified as an internal control for normalization of each sample. All samples were analyzed in triplicate using the 2 2DDCT method. Western blotting for SIRT1. Briefly, 50 mg protein was separated by 8% SDS polyacrylamide gels, and transferred to polyvinyl difluoride membranes (Millipore Corp.). The membranes were blocked in TBS containing 0.1% Tween-20 and 5% nonfat dry milk for 30 min at room temperature, and incubated with antibody to SIRT1 (sc-15404) (15200; Santa Cruz Biotechnology) overnight at 4uC. Then, the membranes were washed by PBS-Tween followed by 1 h incubation at room temperature with horseradish peroxidase-conjugated secondary antibody (155000; Santa Cruz Biotechnology) and detected using the enhanced chemiluminescence (Amersham Life Science).
Bisulfite sequencing for BRCA1 promoter. All the tissues were used for bisulfite sequencing from the non-BRCA1-mutated cases. Genomic DNA extracted from ovarian cancer and normal ovarian tissue with a TIANamp Genomic DNA kit (Tiangen Biotech, Beijing, China) was subjected to bisulfite conversion using the EZ DNA Methylation-Direct kit (Zymo Research, Orange, USA) following the manufacturer's instructions; the conversion efficiency was estimated to be at least 99.6%. It was then amplified by nested PCR. After gel purification, cloning and transformation into E. coli Competent Cells JM109 (TaKaRa), ten positive clones of each sample were sequenced to ascertain the methylation patterns of each CpG locus. Figure 6 | Proposed model of crosstalk between BRCA1 and SIRT1 in ovarian cancer. BRCA1 inactivation events (mutation, promoter methylation, or other pathways) will inhibit SIRT1 expression. However, BRCA1 inactivation induces a substantial increase in NAD levels, and consequently enhances SIRT1 activity. This is a special compensatory mechanism for the loss of SIRT1 expression. The model shows a significant effect of BRCA1 in the maintenance of SIRT1-related biological processes in ovarian cancer. The changes are indicated by red and green arrows. The primers were used for BRCA1 gene promoter (Accession number: NG_005905) were shown in Supplementary Table S3 . The conditions were as follows: 95uC for 2 min, 40 cycles of 30 s at 95uC, 30 s at 56uC and 45 s at 72uC, then 72uC for 7 min. NAD incubation. A2780 and primary ovarian cancer cells were incubated with 0, 5, 25, 125 or 625 mM NAD (Sigma, CA, USA) for 3 h at 37uC. NAD levels assay. For NAD assay, 20 mg of freezed ovarian tissue, or 20 ml packed cultured cells were homogenized in 400 ml BioVsion NAD/NADH Extraction Buffer (BioVsion, CA, USA). The homogenate was ultrafiltered using BioVsion 10-kD cutoff filters (14000 g, 30 min, 4uC). Assays were performed using the NAD/NADH Quantification Kits according to the manufacturer's instructions (BioVsion). SIRT1 activity assay. SIRT1 deacetylase activity was evaluated by using a commercially available CycLex SIRT1/Sir2 Deacetylase Fluorometric Assay Kit (Cyclex Co., Ltd., Nagano, Japan), according to the manufacturer's protocols.
Statistical analysis. Regression analysis was used to examine the possible relationship between BRCA1 levels or NAD levels and SIRT1 levels or SIRT1 activity in ovarian cancer samples. The data are presented as means 6 standard deviations (SD). Statistical differences in the data were evaluated by Student's t-test or one-way analysis of variance as appropriate, and were considered significant at P , 0.05.
